Comparative Pharmacology
Head-to-head clinical analysis: AQNEURSA versus LOCORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQNEURSA versus LOCORTEN.
AQNEURSA vs LOCORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AQNEURSA is a monoclonal antibody that binds to and inhibits the activity of serum amyloid A (SAA), reducing amyloid deposition in tissues.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
AQNEURSA (ursodiol) is administered orally at 13–15 mg/kg/day in 2–4 divided doses for primary biliary cholangitis. For gallstone dissolution, the dose is 8–10 mg/kg/day in 2–3 divided doses, with a maximum of 300 mg twice daily.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe cases).
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Approximately 70-80% of the dose is excreted renally as unchanged drug; 20-30% is eliminated via biliary/fecal routes.
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid